logo
Share SHARE
FONT-SIZE Plus   Neg

Salix, Progenics Announce FDA Extension Of RELISTOR SNDA Goal Date To July 27

Salix Pharmaceuticals, Ltd. (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the Food and Drug Administration, or FDA, has extended the Prescription Drug User Fee Act goal date for the Agency's review of the Supplemental New Drug Application, or sNDA, for RELISTOR (methylnaltrexone bromide) injection for subcutaneous use for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

The FDA has notified Salix that it requires additional time for a full review of the submission and has extended the April 27, 2012 goal date by the standard extension period of three months. The extended user fee goal date is July 27, 2012. The extension requested no additional studies.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Seattle police caught an alleged car thief by remotely locking him inside the stolen BMW 550i with the help of the automaker. The Seattle Police Department said in its blog that the incident took place in Seattle in November. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan.
comments powered by Disqus
Follow RTT